Director Adam Schayowitz of Faeth Therapeutics, Inc. filed a Form 4 on October 27, 2026, disclosing the acquisition of a stock option covering 25,000 shares of common stock with an exercise price of $17.08 per share, granted on October 23, 2026.

Key Highlights

  • Reporting person: Adam Schayowitz, identified as a Director of Faeth Therapeutics, Inc.
  • Security acquired: A stock option (right to buy) covering 25,000 shares of common stock, acquired on October 23, 2026.
  • Exercise price: $17.08 per share, with an expiration date of October 22, 2036.
  • Price paid for option: $0, as stated in the filing.
  • Vesting schedule: 36 equal monthly installments over three years, with full vesting on October 23, 2029, subject to continuous service.
  • Derivative securities beneficially owned following transaction: 25,000, held directly.

Schayowitz Stock Option Grant Details at Faeth Therapeutics

According to the Form 4 filed with the SEC on October 27, 2026, Adam Schayowitz, a Director of Faeth Therapeutics, Inc. (NASDAQ:FTH), acquired a stock option to purchase 25,000 shares of the company's common stock. The transaction date is listed as October 23, 2026, and the option carries an exercise price of $17.08 per share. The filing records the price of the derivative security as $0, indicating no cash consideration was paid at grant.

The filing's footnote discloses that the option vests and becomes exercisable in 36 equal monthly installments over a three-year period, "such that the option is fully vested on the third anniversary of the date of grant, or October 23, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date." The option expires on October 22, 2036. Following the reported transaction, Schayowitz beneficially owns 25,000 derivative securities directly, with no indirect holdings reported.

No non-derivative securities transactions were reported in Table I of the filing. The Form 4 was signed by Josiah Craver as Attorney-in-Fact on October 27, 2026, and was filed as a single reporting person disclosure, not a joint or group filing.

What Was Disclosed

Faeth Therapeutics Director Adam Schayowitz reported the grant of a stock option for 25,000 shares at an exercise price of $17.08, dated October 23, 2026, vesting monthly over three years and expiring October 22, 2036, with $0 paid at acquisition.